

Dr Lo 摘要

To evaluate the safety, feasibility, and early clinical outcomes of two office-based minimally invasive surgical therapies (MIST), Urolift and Rezum, for benign prostatic hyperplasia (BPH) performed under pure local anesthesia with same-day discharge. Prospective cohorts of men with BPH-related lower urinary tract symptoms (LUTS) or obstructive uropathy underwent either Urolift or Rezum between 2023 and 2024. Procedures were performed in the endoscopy room under local anesthesia without general or regional block. Peri-operative outcomes, pain scores, catheter status, hospital stay, and functional outcomes were recorded. Follow-up included International Prostate Symptom Score (IPSS), quality of life (QoL), uroflowmetry, prostate volume, and renal function when applicable. A total of 50 patients were treated (30 Urolift, 20 Rezum). For Urolift, mean prostate volume was 52.4 cc, mean operative time 20 minutes, and mean procedural pain scores were low. All LUTS patients and 85% of retention patients were discharged catheter-free on the same day, with no 30-day readmissions. At 3 months, prostate volume decreased by 14.9%, IPSS improved by 69%, QoL by 50%, and Qmax by 21%. For Rezum, median prostate size was 57.8 ml, and 95% of men with obstructive uropathy were successfully weaned off catheter within a median of 33 days, with stable renal function. At 3 months, no recurrent retention occurred; prostate volume decreased by 38%, median IPSS was 4, QoL 2, and Qmax reached 10.3 ml/s. Both Urolift and Rezum are safe and effective office-based MIST options for BPH, feasible under pure local anesthesia with same-day discharge. Urolift offers rapid symptomatic relief with minimal peri-operative morbidity, while Rezum provides significant prostate volume reduction and durable voiding recovery in patients with obstructive uropathy. These approaches can reduce hospital stay, optimize theatre utilization, and expand access to minimally invasive BPH treatment.